mecamylamine has been researched along with Diabetic Retinopathy in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 9.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
| " The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 5.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campochiaro, PA | 1 |
| Shah, SM | 1 |
| Hafiz, G | 1 |
| Heier, JS | 1 |
| Lit, ES | 1 |
| Zimmer-Galler, I | 1 |
| Channa, R | 1 |
| Nguyen, QD | 1 |
| Syed, B | 1 |
| Do, DV | 1 |
| Lu, L | 1 |
| Monk, J | 1 |
| Cooke, JP | 1 |
| Kengatharan, MK | 1 |
| Hsu, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)[NCT00536692] | Phase 2 | 0 participants | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mecamylamine and Diabetic Retinopathy
| Article | Year |
|---|---|
Topical mecamylamine for diabetic macular edema.
Topics: Administration, Topical; Adolescent; Adult; Aqueous Humor; Chronic Disease; Diabetic Retinopathy; En | 2010 |